Indications
Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.
Composition
- Active substance
- olipudase alfa
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Xenpozyme
- Active substance
- olipudase alfa
- ATC code
- A16AB25
- Therapeutic area
- Acid sphingomyelinase deficiency (ASMD) type A/B or type B
- Marketing authorisation holder
- Sanofi B.V.
- Status
- Authorised